Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the potential of using measurable residual disease (MRD)-guided ibrutinib plus venetoclax treatment in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Niemann notes that while the standard of care for this patient population is rituximab plus venetoclax, as suggested by the Phase III MURANO trial (NCT02005471), the Phase II HOVON-141/VISION trial (NCT03226301) shows that MRD-guided ibrutinib plus venetoclax can achieve sustainable remissions, even if undetectable MRD is not achieved. Dr Niemann highlights that specific driver mutations (BCOR, CCND2, NRAS, and XPO1) can predict which patients are more likely to achieve undetectable MRD and which individuals may require longer treatment, paving the way for personalized treatment approaches in R/R CLL. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
